Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | ADA | P00813 | 2/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29211968 | 0.87 | CYP3A4 (0.59) | CYP3A4CYP2D6FGFR1 | |
| SCHEMBL28900522 | 0.86 | CYP3A4 (0.69) | CYP3A4CYP2D6FGFR1 | |
| SCHEMBL29211974 | 0.86 | CYP3A4 (0.59) | CYP3A4CYP2D6FGFR1 | |
| SCHEMBL29287913 | 0.83 | CYP3A4 (0.59) | CYP3A4CYP2D6FGFR1 | |
| SCHEMBL29287935 | 0.83 | CYP3A4 (0.59) | CYP3A4CYP2D6FGFR1 | |
| SCHEMBL8217400 | 0.81 | CYP3A4 (0.60) | CYP3A4CYP2D6ADAPDE2APDE4A | |
| SCHEMBL23425534 | 0.78 | CYP3A4 (0.78) | CYP3A4CYP2D6 | |
| SCHEMBL28977840 | 0.78 | CYP3A4 (0.62) | CYP3A4CYP2D6FGFR1 | |
| SCHEMBL29287928 | 0.77 | CYP3A4 (0.53) | CYP3A4CYP2D6FGFR1 | |
| SCHEMBL23425533 | 0.77 | CYP3A4 (0.77) | CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109485676-B | Novel nucleoside reverse transcriptase inhibitors for antiviral use | 深圳市塔吉瑞生物医药有限公司 | 2022-07-15 | — | — | CN | disclosed |